← Human Trials & Peer-Reviewed Studies
Three months of abaloparatide treatment rapidly improves bone formation and density: implications for orthopedic preoperative bone health optimization.
Plain-language guide to PMID 42498818 (2026): randomized controlled trial of Abaloparatide in 149 men.
Key Facts
- PMID
- 42498818
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- VanDerwerker NB et al. (6 authors)
- DOI
- 10.1007/s00198-026-08126-y
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Abaloparatide.
This study aims to assess the early response to abaloparatide (ABL) in men and postmenopausal women with osteoporosis at high risk for fracture to inform its potential role in preoperative bone health optimization (BHO).
The researchers aim to assess changes in bone mineral density (BMD) by three months and early changes in bone turnover markers (BTMs).
Why It Was Studied
How long to delay orthopedic surgery for preoperative BHO using ABL remains unclear.
Who Took Part
The study group was 149 men.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
A post-hoc analysis of two randomized ABL trials in men and postmenopausal women with osteoporosis was performed.
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Abaloparatide and who got the comparison, which limits bias.
The primary endpoint was mean percent BMD change at 3-months in the femoral neck, total hip, and lumbar spine.
BTMs P1NP and CTX were also assessed.
What Was Measured
The subject headings attached to it are Bone Density, Bone Density Conservation Agents, Preoperative Care, Osteoporosis, Parathyroid Hormone-Related Protein, Lumbar Vertebrae and Osteoporosis, Postmenopausal.
The authors tagged it with the keywords Abaloparatide, Bone health optimization and Bone mineral density.
What This Means in Plain Language
The paper is a randomized study of Abaloparatide in 149 men.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2026 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Abaloparatide compound page, all human trials.
Our Notes on the Compound
Abaloparatide: A synthetic parathyroid hormone-related peptide (PTHrP) analog used as a bone-building (anabolic) osteoporosis medicine.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.